



## IBA – TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, July 10, 2017, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notifications received on 7 July 2017\*.

<b>Reason for the notification</b>	Upwards crossing of the 3% threshold further to the acquisition of shares –and thus voting rights– held as loan collateral
<b>Persons subject to the notification requirement</b>	IBA SA, issuer
<b>Persons that dispose of voting rights</b>	Norges Bank
<b>Transaction date</b>	05/07/2017
<b>Threshold that is crossed (in %)</b>	3% (statutory threshold) Upwards crossing further to the acquisition of voting rights
<b>Denominator</b>	29 852 549
<b>Voting rights (number)</b>	1 015 762
<b>Voting rights (%)</b>	3,40%
<b>Chain of control</b>	N/A

### About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and

## Press Release

Regulated information



Bloomberg IBAB.BB). More information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

\* Erratum on “7 April 2017” previously communicated.

**For further information, please contact:**

### IBA

**Stephanie Bauwin**

Legal Counsel

+32 10 203 924

[Stephanie.bauwin@iba-group.com](mailto:Stephanie.bauwin@iba-group.com)